Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.
about
Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cellsNuclear signalling by tumour-associated antigen EpCAMEpCAM (CD326) finding its role in cancerCirculating Tumor Cells: A Window Into Tumor Development and Therapeutic EffectivenessAntibody-based immunotherapy for ovarian cancer: where are we at?Prostate cancer relevant antigens and enzymes for targeted drug deliveryCancer stem cells in colorectal cancer from pathogenesis to therapy: controversies and perspectivesCrystal structure and its bearing towards an understanding of key biological functions of EpCAMCirculating and disseminated tumor cells: diagnostic tools and therapeutic targets in motionCharacterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancerCatumaxomab: clinical development and future directionsThe evolving role of catumaxomab in gastric cancerTumor regression in cancer patients by very low doses of a T cell-engaging antibodyEpCAM in carcinogenesis: the good, the bad or the uglyCirculating Tumor Cells: From Theory to Nanotechnology-Based Detection.Fast and selective cell isolation from blood sample by microfiber fabric system with vacuum aspiration.Activator protein 1 (AP-1) contributes to EpCAM-dependent breast cancer invasion.Initial activation of EpCAM cleavage via cell-to-cell contact.Identification of gene interactions associated with disease from gene expression data using synergy networks.Co-regulation analysis of closely linked genes identifies a highly recurrent gain on chromosome 17q25.3 in prostate cancerRelationship between epithelial cell adhesion molecule (EpCAM) overexpression and gastric cancer patients: A systematic review and meta-analysisCancer stem cell marker Musashi-1 rs2522137 genotype is associated with an increased risk of lung cancer.EpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosisEPCAM Expression in Colon Adenocarcinoma and its Relationship with TNM StagingIdentification of genes regulating migration and invasion using a new model of metastatic prostate cancerClinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancerNuclear and cytoplasmic accumulation of Ep-ICD is frequently detected in human epithelial cancers.Predicting targeted drug combinations based on Pareto optimal patterns of coexpression network connectivityRNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule.High interstitial fluid pressure is associated with low tumour penetration of diagnostic monoclonal antibodies applied for molecular imaging purposes.Nuclear Ep-ICD accumulation predicts aggressive clinical course in early stage breast cancer patients.Epithelium percentage estimation facilitates epithelial quantitative protein measurement in tissue specimens.Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110.Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites.The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis.Molecular diagnosis and therapy for occult peritoneal metastasis in gastric cancer patientsMethods for detecting circulating cancer stem cells (CCSCs) as a novel approach for diagnosis of colon cancer relapse/metastasisHigh EpCAM expression is linked to proliferation and lauren classification in gastric cancer.Regulated intramembrane proteolysis and degradation of murine epithelial cell adhesion molecule mEpCAM.An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer.
P2860
Q21136080-4B2B5E4F-ADB8-4EEB-8CD3-6F8625946AFAQ24315870-E5DEAD4C-2436-406F-B06B-9829CF3CC204Q24653692-2344AB72-4392-41BE-A5C9-FD21D3C72C99Q26827815-2E65BB76-9DAD-4B97-A8B8-7000A3867B12Q27000514-58B7E606-2B47-4053-ADF9-DE14A5936FE0Q27013843-097BE60B-8477-4024-9197-CA7E312926D2Q27024651-DC94B609-DF8E-4337-AEE4-5B0823473B67Q27694818-C9907E21-3DCE-498D-989A-AA3043F20C18Q28066285-8E631B34-E441-4C6A-9CE8-F1091F43A14BQ28235980-06CCF890-337B-49DB-BC56-4E1F888C1D61Q28274519-DE90C114-D474-49C3-BC5F-72928E34C63AQ28290511-C7753631-01D3-4DBB-8BBD-B0B3A2856509Q28290910-648EADF1-B7D8-4BAB-91BC-9ECBD48536DEQ28293163-59C4DA9E-FA49-486F-B5F8-DA83707EFB3EQ30363234-4EEF0E4C-8F4D-454C-87B1-259077C0FF36Q30368315-11F90C0F-FF34-4E74-A9B5-598BAA10627AQ30427356-57237E8D-4F75-4749-AB9D-2564AC085471Q30898801-79717748-A006-4AC0-894E-A86EE4C6ABB8Q31144746-513E8257-7C6A-4747-A6F7-89E2DB4411E4Q33381372-113265A2-8FF1-4416-93FF-18857D79B1F0Q33558687-A75C6BDE-5EA5-45B8-A7CF-2649161E90F6Q33560334-6672A74A-EC9B-437E-9CC8-D3FF544EC5B7Q33616879-A2409444-5105-4535-8D12-B5F683B62968Q33697327-AF4982E7-6A3A-4491-9405-1A7C96C23AEAQ33714753-F9B9B953-98E3-455D-AB34-8BE8AAE33379Q33750119-33F0AD99-00D0-445D-A95A-51A7D166B2FCQ33770286-8C9ADCA6-AC64-49FA-A4CE-99A2380F1D82Q33772585-6737AA4D-1EC3-49DC-A53A-080C9CC15C42Q33807710-42075E43-1BC5-44B2-82C2-FF53CC5EB4B4Q34270696-FD73AE41-BD27-4902-82FF-FB7CBCCAF0D5Q34308781-40CA2DE7-5289-4477-8146-64C10B7648B4Q34455382-7B488EFC-F170-4BED-92B8-37536EF5391FQ34570056-A69AE044-5CDD-421B-9577-DEAA06A44B9DQ34621433-8A15608B-CC94-4BCE-A486-10634B13D602Q34624096-80DBDD84-A639-416F-BDCE-ADDF80E5B8D6Q34750564-15BF2735-9331-4524-BB79-F7FD8480859FQ34797751-776297F8-2AEE-4EB3-B494-4E45469C679EQ34800662-12A5CF8C-BC69-436B-8389-97583002C1C8Q34979489-949B9D14-93A3-4653-8258-04C94E08FFB1Q34994161-50AD83F4-78A7-4DF6-AB2E-6D3E121A133F
P2860
Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Frequent high-level expression ...... ch, prostate and lung cancers.
@ast
Frequent high-level expression ...... ch, prostate and lung cancers.
@en
type
label
Frequent high-level expression ...... ch, prostate and lung cancers.
@ast
Frequent high-level expression ...... ch, prostate and lung cancers.
@en
prefLabel
Frequent high-level expression ...... ch, prostate and lung cancers.
@ast
Frequent high-level expression ...... ch, prostate and lung cancers.
@en
P2093
P2860
P356
P1476
Frequent high-level expression ...... ach, prostate and lung cancers
@en
P2093
L Bubendorf
L Terracciano
P A Baeuerle
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602924
P407
P577
2006-01-01T00:00:00Z